Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study
Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study
复制标题
DOI：
10.1016/j.jhep.2012.07.028
复制
发表时间：
2012-12-01
影响因子：
25.7
通讯作者：
Janssen, Harry L. A.
中科院分区：
文献类型：
--
作者：
Koehler, Edith M.;Schouten, Jeoffrey N. L.;Janssen, Harry L. A.
背景与目的：非酒精性脂肪性肝病（NAFLD）的患病率似乎随着年龄的增长而增加。然而，关于老年人NAFLD患病率的数据有限。我们的目的是确定NAFLD的患病率和危险因素在老年population.Methods：这项研究是基于参与者的人口为基础的鹿特丹研究。每个参与者都接受了采访，并在研究中心进行了临床检查，包括空腹采血，肝脏超声检查和人体测量评估。有序和逻辑回归分析被用来评估协变量和NAFLD（严重程度）之间的关联。结果：来自2811名参与者（平均年龄76.4 +/- 6.0岁）的数据进行了分析。NAFLD的患病率为35.1%。NAFLD患病率随年龄增长而下降（p 102 cm男性（OR 4.89; CI 4.00-5.96; p = 100 mg/dl）或药物治疗血糖升高（OR 2.11，95% CI 1.72-2.59; p = 130/85 mmHg或药物治疗血压升高（OR 1.80，95%血压升高（OR 1.80，95% CI 1.08-3.01; 1.08-3.01; p = 0.03），甘油三酯>= 150 mg/dl或用血清降脂剂治疗（OR 1.56，95%CI 1.28-1.91; p
Background & Aims: The prevalence of non-alcoholic fatty liver disease (NAFLD) appears to increase with age. However, limited data are available concerning the prevalence of NAFLD in the elderly. Our aim was to determine the prevalence and risk factors of NAFLD in an elderly population.Methods: This study was based on participants in the population-based Rotterdam Study. Each participant was interviewed and had a clinical examination at the research center, including a fasting blood collection, liver ultrasonography, and anthropometric assessment. Ordinal and logistic regression analysis was used to assess associations between covariables and (severity of) NAFLD.Results: Data from 2811 participants (mean age 76.4 +/- 6.0 years) were analyzed. The prevalence of NAFLD was 35.1%. The prevalence of NAFLD decreased with advancing age (p 102 cm for men (OR 4.89; CI 4.00-5.96; p = 100 mg/dl or drug treatment for elevated blood glucose (OR 2.11, 95% CI 1.72-2.59; p = 130/85 mmHg or drug treatment for elevated blood pressure (OR 1.80, 95% for elevated blood pressure (OR 1.80, 95% CI 1.08-3.01; 1.08-3.01; p = 0.03), and triglycerides >= 150 mg/di or treatment with serum lipid reducing agents (OR 1.56, 95% Cl 1.28-1.91; p